drugset / Trial / NCT00590278

A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer

NCT00590278

Phase 2 Completed 49 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The pilot study is designed to investigate the value of Neo-adjuvant Tomudez in combination with radiotherapy in patients with inoperable or recurrent rectal cancer in terms of response rate and increasing the resectability of initially inoperable rectal cancer.

Timeline

Start
2002-08
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Raltitrexed Small molecule

Indications